• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Saturday 04/21/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

AIPT

  • 4:46 PM

    Richard Gabriel, BS, MBA is a board member of Precision Therapeutics and spearheaded the licensing of new technologies for 3D cell culturing from 48 Hour Discovery, SyntArray and CellBridge MINNEAPOLIS, April 09, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has engaged Richard Gabriel as a consultant to lead the external business development strategy for TumorGenesis, Inc., its

    Read more
  • 12:17 PM

    Company reports strengthening STREAMWAY® System sales and new strategic focus on the emerging precision medicine market MINNEAPOLIS, April 02, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three and twelve months ended December 31, 2017 and provides a business update on its plans to transition its strategic focus to precision medicine and the Contract Research Organization

    Read more
  • 10:06 AM

    Sixteen STREAMWAY Systems sold in Q1 2018, compared with five units sold in Q4 2017 and three sold in Q1 2016 MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), today provided a sales update from its Skyline Medical division, producer of the FDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal. Skyline Medical sold 16 STREAMWAY Systems in the first quarter of 2018, to a combination of both new customers as well as its existing

    Read more
  • 9:42 AM

    MINNEAPOLIS, (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the fiscal year 2017 on April 2, 2018 after U.S. markets close. Management will also hold a conference call to provide a general business update and discuss upcoming milestones. The conference call is scheduled to begin at 4:30 p.m. Eastern Time. A webcast of

    Read more
  • 9:09 AM

    MINNEAPOLIS, March 21, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with CellBridge Incorporated (“CellBridge”) which grants it access to CellBridge’s 3D biomimetic support technology. This follows the Company’s recently announced license agreements with SyntArray, LLC and 48Hour Discovery and is the latest milestone in the Company’s strategy to bring together ground-breaking technologies to develop the next generation of patient derived (“PDx”) tumor models for

    Read more
  • 1:52 PM

    MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with 48Hour Discovery (“48HD”) which grants it access to 48HD’s ligand discovery technology. This follows a license agreement with SyntArray, LLC, announced on March 13th, and is the latest milestone in the Company’s strategy to bring together ground-breaking technologies to develop the next generation of patient derived (“PDx”) tumor models for

    Read more
Public Wire Banner